bioAffinity Technologies, Inc.

BIAF Healthcare Diagnostics & Research

In the quarter to June 2026, revenue grew 19.0%, EPS grew 87.5%, free cash flow fell 23.7% and total debt rose 569.7%, each against the same quarter a year earlier.

3.73 0.23 −5.81%
Market cap
$5.1M
P/E
0.0×
Fwd P/E
−0.2×
Dividend yield
—
F-score
2/9
Altman Z
−10.54
Beneish M
−5.49
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 2 2 3
ROE
(245.18%) (301.83%) (622.65%) (1,860.15%)
ROA
(162.88%) (170.65%) (235.39%) (245.51%)
ROIC
(458.54%) (438.42%) (613.56%) (408.67%)
Return on Tangible Assets
(224.78%) (302.76%) (1,131.70%) (1,013.64%)
Average Days of Receivables
24.18 32.10 44.19 55.35
Free Cash Flow per Share
(119.65) (81.79) (36.46) (33.16)
Free Cash Flow
(8.51) (9.39) (10.93) (11.56)
Capital Expenditures
(0.06) (0.06) (0.02) (0.09)
Other line items
Cash ROIC
(50.78%) (65.17%) (148.21%) (171.18%)
Accounts Receivable Turnover
7.63 7.33 6.87 8.96
Accounts Payable Turnover
5.67 4.83 3.42 3.61
Inventory Turnover
161.35 104.24 64.91 61.06
Average Days of Payables
70.24 65.79 80.58 91.73
Days of Inventory on Hand
2.63 4.62 7.51 7.79
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
28.60% 33.90% 40.06% 45.14%
Selling, General and Administrative Expense of Revenue
144.56% 160.88% 189.10% 192.29%
Share Based Compensation of Revenue
12.39% 10.90% 6.35% 15.80%
Interest Coverage
(184.08) (237.58) (264.59) (275.76)
Operating CF/Net income
0.57 0.63 0.69 0.76
Depreciation/Fixed assets
1.76 1.90 1.88 1.32
Capex/Depreciation
(0.11) (0.12) (0.03) (0.22)
Revenue per Share
95.31 53.68 18.88 16.93
Operating CF per Share
(118.80) (81.26) (36.40) (32.90)
Capex per Share
(0.85) (0.53) (0.05) (0.26)
Capex to Sales
0.01 0.01 0.00 0.02

Fold the line items

Columns are period end dates · fundamentals updated 2 Oct 2026